Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Conditions
Agitation · Alzheimer Disease
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Local Institution - 0046, Homewood, Alabama, United States
University of Alabama - Huntsville Regional Medical Campus, Huntsville, Alabama, United States
Local Institution - 0048, Phoenix, Arizona, United States
Local Institution - 0040, Scottsdale, Arizona, United States
Local Institution - 0017, Anaheim, California, United States
Inland Psychiatric Medical Group., Chino, California, United States
Kaizen Brain Center, La Jolla, California, United States
University of California San Diego - La Jolla, La Jolla, California, United States
Shreenath Clinical Service - Lakewood, Lakewood, California, United States
Accellacare - Sherman Oaks, Sherman Oaks, California, United States
Next Level Clinical Trials, West Covina, California, United States
Local Institution - 0028, West Hills, California, United States
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
Local Institution - 0067, Washington D.C., District of Columbia, United States
Local Institution - 0053, Washington D.C., District of Columbia, United States
Arrow Clinical Trials, Daytona Beach, Florida, United States
ClinCloud, Maitland, Florida, United States
Local Institution - 0007, Maitland, Florida, United States
Local Institution - 0022, Miami, Florida, United States
Local Institution - 0010, Miami, Florida, United States
Local Institution - 0001, Tampa, Florida, United States
Charter Research - Lady Lake, The Villages, Florida, United States
Local Institution - 0026, Atlanta, Georgia, United States
CenExel iResearch, LLC, Decatur, Georgia, United States
CenExel iResearch, LLC, Savannah, Georgia, United States
Local Institution - 0004, Honolulu, Hawaii, United States
Local Institution - 0011, Marrero, Louisiana, United States
Local Institution - 0051, South Dartmouth, Massachusetts, United States
Boeson Research, Missoula, Montana, United States
Be Well Clinical Studies - Omaha, Omaha, Nebraska, United States
Local Institution - 0041, Las Vegas, Nevada, United States
Local Institution - 0059, Livingston, New Jersey, United States
University at Buffalo - UBMD Neurology, Buffalo, New York, United States
The Feinstein Institute for Medical Research, Manhasset, New York, United States
Mid Hudson Medical Research, New Windsor, New York, United States
Local Institution - 0064, Staten Island, New York, United States
Research Central LLC (DBA Ichor Research), Syracuse, New York, United States
New Hope Clinical Research, Charlotte, North Carolina, United States
UNC Health REX Hospital, Raleigh, North Carolina, United States
Cleveland Clinic, Cleveland, Ohio, United States
Thomas Jefferson University - Vickie & Jack Farber Institute for Neuroscience, Philadelphia, Pennsylvania, United States
K2 Medical Research - East Providence, East Providence, Rhode Island, United States
Local Institution - 0031, Chattanooga, Tennessee, United States
Neurology Clinic, P.C., Cordova, Tennessee, United States
Vanderbilt University Medical Center- Village, Nashville, Tennessee, United States
Pinnacle Clinical Research, Austin, Texas, United States
Horizon Clinical Research Center - Houston, Cypress, Texas, United States
ANESC Research, El Paso, Texas, United States
North Pointe Psychiatry - Flower Mound, Flower Mound, Texas, United States
Local Institution - 0020, Houston, Texas, United States
Stryde Research - Plano, Plano, Texas, United States
Be Well Clinical Studies, Round Rock, Texas, United States
Boeson Research - Provo, Provo, Utah, United States
Study leads
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb